Research memoHansoh Pharmaceutical Group Company Limited (3692.HK) · HKSEMemo of October 18, 2026

Hansoh dividend: history, cash cover and yield

Hansoh paid dividends every year shown; in 2025, shareholder payouts were RMB2,012.184 million. Its 2025 real free cash flow per share was RMB1.04, above diluted EPS of RMB0.93, with RMB0.73 remaining after dividends and buybacks.

0.34
Dividend paid per share, 2025
1.4%
Dividend yield
3.8%
Real free cash flow yield
3.9%
Free cash flow yield
Read the full Hansoh memoYour first report is free · no card
Every number traced to Hansoh's filings8 chapters · 15,577 words134 sources cited

How much does Hansoh pay per share?

Hansoh paid dividends every year shown. In 2025, shareholder payouts were RMB2,012.184 million. The rest of that year’s free cash flow stayed available for research, licensing, facilities or reserves. Hansoh also generated RMB6,738 million from operations in 2025 and spent RMB458 million on capital expenditure, mainly workshops and equipment.

Dividend per share against free cash flow per share (RMB per share)0.060.3420210.120.3820220.110.4520230.310.5820240.341.042025Dividends paid, per shareReal free cash flow per share
What one share getsRMB per share
20252024202320222021
EPS, diluted0.930.730.520.440.44
Real free cash flow per share1.040.580.450.380.34
− Paid to minority owners, per share0.000.000.000.000.00
− Dividends paid, per share0.340.310.110.120.06

Does Hansoh's cash cover its dividend?

Hansoh’s real free cash flow margin rose across the five-year period and reached 41.4% in 2025. Hansoh’s real free cash flow per share reached RMB1.04, above diluted EPS of RMB0.93. RMB0.73 remained after dividends and buybacks; net cash rose across the five years shown.

Follow the money: where the free cash flow wentRMB millions
20252024202320222021
Free cash flow6,359.4363,616.4992,872.1352,450.7122,104.74
− Dividends paid2,012.1841,858.348652.082712.184380.866
− Share buybacks033.693114.86576.61857.969
= Free cash flow not paid out4,347.2521,724.4582,105.1881,661.911,665.905
Paid out, % of free cash flow31.6%52.3%26.7%32.2%20.8%

What this means. The company did not keep all of its leftover free cash as cash: it put much of it into investments, so cash can rise or fall even when free cash flow is positive.

What could change Hansoh's dividend?

The dividend base case increases from CNY0.40 to CNY0.48 per share as marketed-product growth supports distributions, but R&D and uneven collaboration income restrain the pace. The bear case cuts the dividend to CNY0.26, while the bull case raises it to CNY0.59. The base starts above the 2025 equivalent of about CNY0.367 and reflects the higher 2026 interim declaration.

The bull case would gain weight if pivotal data lead to applications and approvals, followed by hospital access and sustained prescribing. Faster dividend growth would support the view if operating cash flow improves. Partner milestones would matter most in 2028–2029 because they could validate future royalties.

The forecast's tablebase case, then bear / bull in brackets; CNY millions, per share in CNY, unless shown
October 2027October 2028October 2029
Earnings6,612 (5,775 / 7,360)7,296 (5,742 / 8,610)8,112 (5,580 / 10,080)
Shares (millions)6,072 (6,068 / 6,074)6,080 (6,072 / 6,084)6,088 (6,076 / 6,177)
Dividends per share0.40 (0.34 / 0.44)0.44 (0.30 / 0.51)0.48 (0.26 / 0.59)
Price to earnings22.00 (16.00 / 28.00)20.00 (14.00 / 30.00)18.00 (12.00 / 32.00)

What is Hansoh's dividend yield at today's price?

The final-date outcomes are wide. The bear case is HKD12.94 and the bull case is HKD61.30. Today’s price is HKD31.74, so the model offers substantial downside risk alongside a large upside tail.

From the full memo · 1. The business

Hansoh Pharmaceutical Group is a Chinese prescription-drug company: it discovers, makes and sells medicines, with cancer treatment at its center. To understand its business, follow renminbi from a patient’s treatment through distributors and partners into Hansoh’s accounts, then out again through research, manufacturing, selling and operations.

Continue reading, free
Your first report is free · no card

Where these numbers come from

More on Hansoh

Hansoh stock forecast

Its rivals

BeOne (6160.HK)Innovent (1801.HK)

Browse

All stocksHang Seng companiesCompanies H
The full Hansoh memoYour first report is free
Read it